Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease ; volume:20 ; number:1 ; day:9 ; month:1 ; year:2020 ; pages:1-12 ; date:12.2020
BMC neurology ; 20, Heft 1 (9.1.2020), 1-12, 12.2020
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-019-1591-0
- URN
-
urn:nbn:de:101:1-2020052417063486796538
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wattmo, Carina
- Blennow, Kaj
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease